MNG154
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.553
- DNA_REPAIR+0.301
- PANCREAS_BETA_CELLS+0.279
- MYC_TARGETS_V1+0.274
- OXIDATIVE_PHOSPHORYLATION+0.254
- MYOGENESIS+0.239
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.219
- WNT_BETA_CATENIN_SIGNALING+0.214
- UV_RESPONSE_UP+0.212
- P53_PATHWAY+0.191
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.438
- INTERFERON_GAMMA_RESPONSE-0.398
- UV_RESPONSE_DN-0.390
- PROTEIN_SECRETION-0.388
- ANDROGEN_RESPONSE-0.344
- COMPLEMENT-0.294
- TNFA_SIGNALING_VIA_NFKB-0.292
- INFLAMMATORY_RESPONSE-0.282
- KRAS_SIGNALING_UP-0.282
- IL6_JAK_STAT3_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 701e70ac-31d2-4e78-95e1-3fa2bb466e83 | — | — | 0.832 |
| 2 | TCGA-XF-AAMH-01A-11R-A42T-07 | — | — | 0.827 |
| 3 | 0ffd0bed-35a4-4fec-9d56-1d4ae5dcb507 | — | — | 0.815 |
| 4 | BS_4D9DD103 | Med | Medulloblastoma | 0.814 |
| 5 | BS_K3ER45RV | Med | Medulloblastoma | 0.798 |
| 6 | SRR12475106 | — | — | 0.781 |
| 7 | MNG1117 | — | — | 0.772 |
| 8 | TCGA-E2-A2P5-01A-11R-A19W-07 | — | B | 0.766 |
| 9 | TCGA-A2-A3XU-01A-12R-A22U-07 | — | E | 0.762 |
| 10 | TCGA-UY-A78M-01A-21R-A352-07 | — | — | 0.759 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.553 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.301 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.279 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.274 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.254 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.239 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.219 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.214 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.212 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.191 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.188 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.179 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.163 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.155 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.134 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.111 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.107 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.064 | Inavolisib | — uncovered |
| COAGULATION | 0.048 | Binimetinib | — uncovered |